{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:08:07Z","timestamp":1791209287106,"version":"4.1.0"},"reference-count":41,"publisher":"American Chemical Society (ACS)","issue":"10","license":[{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T00:00:00Z","timestamp":1787616000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R43AI162348"],"award-info":[{"award-number":["R43AI162348"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Intracellular infections impose fundamental physicochemical barriers that can disrupt antibiotic synergy observed under well-mixed in vitro conditions. Mycobacterium abscessus, a macrophage-resident pathogen, exemplifies this challenge, as co-administered drugs must traverse multiple membrane barriers and achieve coordinated intracellular exposure. The combination of clofazimine (CFZ) and amikacin (AMK) exhibits robust, time-dependent synergy in broth, yet their divergent physicochemical properties (lipophilic versus hydrophilic) predict differential intracellular access. Here, we evaluated whether formulation architecture can mitigate this spatial and temporal separation. CFZ and AMK were engineered either as physical mixtures of micronized powders or as spray-dried composite particles across multiple drug ratios and compared in terms of aerosol performance and intracellular efficacy in a THP-1 macrophage infection model. Neither drug alone achieved meaningful intracellular killing despite activity in broth. In contrast, combination efficacy was strongly formulation-dependent and exhibited a non-monotonic relationship with composition. Physical mixtures were most effective at CFZ-rich ratios, whereas spray-dried composites achieved superior killing at an intermediate mass ratio (1:4 CFZ\/AMK) and displayed a delayed-onset kinetic profile consistent with architecture-dependent temporal drug availability. Aerosol studies showed that composite particles generally improved dispersibility and reduced bulk aerodynamic fractionation between the two drugs relative to physical mixtures, although this effect was condition-dependent. Together, these findings indicate that intracellular efficacy is governed not solely by drug identity or dose, but by formulation-controlled spatial and temporal drug presentation. This work establishes formulation architecture as a critical design variable for translating antibiotic synergy into biologically constrained environments.<\/jats:p>","DOI":"10.1021\/acs.molpharmaceut.6c00473","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:37:56Z","timestamp":1788219476000},"page":"4904-4920","source":"Crossref","is-referenced-by-count":0,"title":["Formulation Design Dictates the Pulmonary Delivery and Antimicrobial Efficacy of Clofazimine\u2212Amikacin Combinations against\n                    <i>Mycobacterium abscessus<\/i>"],"prefix":"10.1021","volume":"23","author":[{"given":"Zachary","family":"Warnken","sequence":"first","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Trementozzi","sequence":"additional","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3157-5021","authenticated-orcid":true,"given":"Mercy","family":"Okezue","sequence":"additional","affiliation":[{"name":"University of Michigan , , 1700 E. Huron Street , , ,","place":["Ann Arbor, Michigan, United States, 48104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia P.","family":"Martins","sequence":"additional","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagruti","family":"Parekh","sequence":"additional","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-239X","authenticated-orcid":true,"given":"Mariana","family":"Romero-Gonzalez","sequence":"additional","affiliation":[{"name":"University of Michigan , , 1700 E. Huron Street , , ,","place":["Ann Arbor, Michigan, United States, 48104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziting","family":"Chen","sequence":"additional","affiliation":[{"name":"University of Michigan , , 1700 E. Huron Street , , ,","place":["Ann Arbor, Michigan, United States, 48104"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Koleng","sequence":"additional","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh D. C.","family":"Smyth","sequence":"additional","affiliation":[{"name":"LLC , , 8222 N Lamar F60 , , ,","place":["Austin, Texas, United States, 78753"]},{"name":"University of Texas , , 2409 University Avenue , , ,","place":["Austin, Texas, United States, 78712"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5456-5427","authenticated-orcid":true,"given":"Ashlee D.","family":"Brunaugh","sequence":"additional","affiliation":[{"name":"University of Michigan , , 1700 E. Huron Street , , ,","place":["Ann Arbor, Michigan, United States, 48104"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"2","key":"2026100509322557500_cit1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1165\/rcmb.2008-0138oc","article-title":"The antioxidant mimetic, MnTE-2-PyP, reduces intracellular growth of Mycobacterium abscessus","volume":"41","author":"Oberley-Deegan","year":"2009","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"1","key":"2026100509322557500_cit2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ccm.2014.10.002","article-title":"Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review","volume":"36","author":"Prevots","year":"2015","journal-title":"Clin Chest Med."},{"issue":"5","key":"2026100509322557500_cit3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"2026100509322557500_cit4","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3389\/fmicb.2019.01977","article-title":"Clinical Efficacy and Adverse Effects of Antibiotics Used to Treat Mycobacterium abscessus Pulmonary Disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front. Microbiol."},{"issue":"1","key":"2026100509322557500_cit5","doi-asserted-by":"publisher","first-page":"100017","DOI":"10.1016\/j.clinme.2024.100017","article-title":"Non-tuberculous mycobacterial pulmonary disease (NTM-PD): Epidemiology, diagnosis and multidisciplinary management","volume":"24","author":"Kumar","year":"2024","journal-title":"Clinical Medicine"},{"key":"2026100509322557500_cit6","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijid.2023.01.032","article-title":"Epidemiological trends in nontuberculous mycobacterial infection among people with cystic fibrosis in Germany","volume":"129","author":"Steindor","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"2026100509322557500_cit7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline: Executive Summary","volume":"71","author":"Daley","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"4","key":"2026100509322557500_cit8","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1128\/AAC.01275-08","article-title":"A novel gene, erm (41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae","volume":"53","author":"Nash","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026100509322557500_cit9","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.3389\/fmicb.2018.02179","article-title":"The Role of Antibiotic-Target-Modifying and Antibiotic-Modifying Enzymes in Mycobacterium abscessus Drug Resistance","volume":"9","author":"Luthra","year":"2018","journal-title":"Front. Microbiol."},{"issue":"2","key":"2026100509322557500_cit10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/BF01964420","article-title":"Intracellular distribution and activity of antibiotics","volume":"10","author":"Tulkens","year":"1991","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"2026100509322557500_cit11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mimet.2018.03.020","article-title":"Evaluation of the intracellular activity of drugs against Mycobacterium abscessus using a THP-1 macrophage model","volume":"148","author":"Molina-Torres","year":"2018","journal-title":"J. Microbiol. Methods"},{"issue":"12","key":"2026100509322557500_cit12","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1128\/AAC.44.12.3249-3256.2000","article-title":"Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance","volume":"44","author":"Kotra","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"issue":"12","key":"2026100509322557500_cit13","doi-asserted-by":"publisher","first-page":"10276","DOI":"10.1074\/jbc.M110","article-title":"Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species","volume":"286","author":"Yano","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6","key":"2026100509322557500_cit14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1128\/AAC.23.6.835","article-title":"Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin","volume":"23","author":"Bryan","year":"1983","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"2026100509322557500_cit15","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1128\/aac.02615-15","article-title":"Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin","volume":"60","author":"Ferro","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"issue":"4","key":"2026100509322557500_cit16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","article-title":"High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria","volume":"35","author":"Shen","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"12","key":"2026100509322557500_cit17","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/aac.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"issue":"10","key":"2026100509322557500_cit18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047494","article-title":"Macrophages Sequester Clofazimine in an Intracellular Liquid Crystal-Like Supramolecular Organization","volume":"7","author":"Baik","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"2026100509322557500_cit19","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1128\/aac.01731-12","article-title":"Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response","volume":"57","author":"Baik","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"1","key":"2026100509322557500_cit20","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/pharmaceutics14010017","article-title":"An Adaptive Biosystems Engineering Approach towards Modeling the Soluble-to-Insoluble Phase Transition of Clofazimine","volume":"14","author":"Willmer","year":"2021","journal-title":"Pharmaceutics"},{"issue":"4","key":"2026100509322557500_cit21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1128\/aac.43.4.727","article-title":"Aminoglycosides: Activity and Resistance","volume":"43","author":"Mingeot-Leclercq","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"2026100509322557500_cit22","unstructured":"Food and Drug Administration\n          \n          Approval Package for Application Number 207356Orig1s000 (\n          Arikacye\n          ), 2018."},{"issue":"12","key":"2026100509322557500_cit23","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"2026100509322557500_cit24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"issue":"6","key":"2026100509322557500_cit25","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment Preference Among People With Cystic Fibrosis: The Importance of Reducing Treatment Burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"issue":"1\u22122","key":"2026100509322557500_cit26","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ijpharm.2018.05.036","article-title":"Formulation techniques for high dose dry powders","volume":"547","author":"Brunaugh","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"4","key":"2026100509322557500_cit27","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1089\/jam.2006.19.456","article-title":"Effect of dry powder inhaler resistance on the inspiratory flow rates and volumes of cystic fibrosis patients of six years and older","volume":"19","author":"Tiddens","year":"2006","journal-title":"J. Aerosol Med."},{"issue":"5","key":"2026100509322557500_cit28","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1002\/jps.20916","article-title":"Physical Characterization of Component Particles Included in Dry Powder Inhalers. I. Strategy Review and Static Characteristics","volume":"96","author":"Hickey","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"2026100509322557500_cit29","article-title":"Clofazimine","author":"United States Pharmacopeial Convention","year":"2019"},{"issue":"3","key":"2026100509322557500_cit30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/chromsci\/bmw169","article-title":"Assay Development for Aminoglycosides by HPLC with Direct UV Detection","volume":"55","author":"Blanchaert","year":"2016","journal-title":"J. Chromatogr. Sci."},{"issue":"1","key":"2026100509322557500_cit31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s00011-007-6115-5","article-title":"Optimized THP-1 differentiation is required for the detection of responses to weak stimuli","volume":"56","author":"Park","year":"2007","journal-title":"Inflamm Res"},{"key":"2026100509322557500_cit32","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jim.2016.01.012","article-title":"The choice of phorbol 12-myristate 13-acetate differentiation protocol influences the response of THP-1 macrophages to a pro-inflammatory stimulus","volume":"430","author":"Lund","year":"2016","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"2026100509322557500_cit33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008668","article-title":"The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages","volume":"5","author":"Daigneault","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"2026100509322557500_cit34","doi-asserted-by":"publisher","first-page":"160185","DOI":"10.1098\/rsob.160185","article-title":"The distinct fate of smooth and rough Mycobacterium abscessus variants inside macrophages","volume":"6","author":"Roux","year":"2016","journal-title":"Open Biol."},{"issue":"5","key":"2026100509322557500_cit35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"25","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"issue":"4","key":"2026100509322557500_cit36","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1128\/mr.51.4.439-457.1987","article-title":"Bacterial uptake of aminoglycoside antibiotics","volume":"51","author":"Taber","year":"1987","journal-title":"Microbiol. Rev."},{"issue":"8","key":"2026100509322557500_cit37","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1128\/AAC.00395-15","article-title":"Mode of Action of Clofazimine and Combination Therapy with Benzothiazinones against Mycobacterium tuberculosis","volume":"59","author":"Lechartier","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"2026100509322557500_cit38","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline","volume":"72","author":"Cholo","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"issue":"1","key":"2026100509322557500_cit39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1208\/s12248-013-9537-8","article-title":"Synergistic antibiotic combination powders of colistin and rifampicin provide high aerosolization efficiency and moisture protection","volume":"16","author":"Zhou","year":"2014","journal-title":"AAPS J."},{"issue":"5","key":"2026100509322557500_cit40","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1208\/s12248-016-9934-x","article-title":"How Much Surface Coating of Hydrophobic Azithromycin Is Sufficient to Prevent Moisture-Induced Decrease in Aerosolisation of Hygroscopic Amorphous Colistin Powder?","volume":"18","author":"Zhou","year":"2016","journal-title":"AAPS J."},{"key":"2026100509322557500_cit41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fimmu.2019.00125","article-title":"Phagosome Escape of Rough Mycobacterium abscessus Strains in Murine Macrophage via Phagosomal Rupture Can Lead to Type I Interferon Production and Their Cell-To-Cell Spread","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Immunol."}],"container-title":["Molecular Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.molpharmaceut.6c00473","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4904\/67407030\/mp6c00473.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article-pdf\/23\/10\/4904\/67407030\/mp6c00473.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:49:20Z","timestamp":1791208160000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/mpohbp\/article\/23\/10\/4904\/5328966\/Formulation-Design-Dictates-the-Pulmonary-Delivery"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,25]]},"published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6c00473","relation":{},"ISSN":["1543-8384","1543-8392"],"issn-type":[{"value":"1543-8384","type":"print"},{"value":"1543-8392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}